| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10K | — | -57.5% |
| SG&A Expense | $12K | — | -36.2% |
| Operating Income | -$71K | — | +23.5% |
| Net Income | -$75K | — | +10.1% |
| EPS (Basic) | -$0.01 | — | — |
| EPS (Diluted) | -$0.01 | — | — |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $5K | +15.1% | -28.0% |
| Current Assets | $56K | -51.1% | -73.0% |
| Total Assets | $67K | -46.8% | -69.5% |
| Current Liabilities | $341K | +4.9% | +24.1% |
| Stockholders' Equity | -$273K | -37.7% | -394.1% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$56K | — | +45.2% |
| Investing Cash Flow | $0 | — | -100.0% |